The financials
Collegium Pharmaceutical, Inc. by the numbers
Collegium Pharmaceutical, Inc. (COLL) reported revenue of $194M in Q1 2026 (quarter ended March 31, 2026), up 8.9% from the same quarter a year earlier. That came with a gross margin of 61% and net income of $14M (7.5% of revenue). For the full year FY2025, revenue was $781M (+24% year on year) and net income $63M. Its largest product in 2026-Q1 was Belbuca at $53M, 27% of the disclosed total, just ahead of Xtampza ER at 26%.
| Income statement | Q1 2026 | Q1 2025 | Change |
|---|---|---|---|
| Revenue | $194M | $178M | +8.9% |
| Gross profit | $117M | $97M | +20% |
| Operating income | $31M | $22M | +42% |
| Net income | $14M | $2.4M | +500% |
| Diluted EPS | $0.40 | $0.07 | +471% |
| Product | Revenue | Share |
|---|---|---|
| Belbuca | $53M | 27% |
| Xtampza ER | $51M | 26% |
| Jornay Pm | $39M | 20% |
| Nucynta IR | $26M | 13% |
| Nucynta ER | $18M | 9.4% |
| Symproic | $4.2M | 2.2% |
| Nucynta ERAG | $1.4M | 0.7% |
| Nucynta IRAG | $1.3M | 0.7% |
Business Segments
Revenue split by product segment, from SEC XBRL filings.
Latest period: Q1 2026Total $193.5M (-7.6%)
Symproic grew +49% year on yearNucynta ER -7.4% year on year
Segment Latestquarter on quarteryear on year
- Belbuca$52.6M$52.6MQoQ -9.6%year on year +1.9%-9.6%+1.9%
- Xtampza ER$50.8M$50.8MQoQ -year on year +6.6%-+6.6%
- Jornay Pm$38.9M$38.9MQoQ -7.0%year on year +36%-7.0%+36%
- Nucynta IR$26.1M$26.1MQoQ -year on year -4.9%--4.9%
- Nucynta ER$18.2M$18.2MQoQ -year on year -7.4%--7.4%
- Symproic$4.2M$4.2MQoQ +4.2%year on year +49%+4.2%+49%
- Nucynta ERAG$1.4M$1.4MQoQ -year on year ---
- Nucynta IRAG$1.3M$1.3MQoQ -year on year ---
- Nucynta Er--QoQ -year on year ---
- Nucynta Ir--QoQ -year on year ---
- Xtampza--QoQ -year on year ---
Drug Manufacturers - Specialty & Generic
Ranks #13 of 28 by Smart Score